纤维肌痛综合征中的破坏性补偿机制及其与药理学剂的关联
Fernanda M Q Silva1, Kevin Pacheco-Barrios1,2, Felipe Fregni3
1Neuromodulation Center, Center for Clinical Research Learning, Spaulding Rehabilitation Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Experimental brain research
|October 5, 2024
概括
纤维肌痛 (FMS) 扰乱了大脑的抑制功能,影响了疲劳和疼痛处理. 经磁刺激 (TMS) 显示与FMS严重程度和治疗因素相关的皮质刺激性发生变化.
科学领域:
- 神经科学是一个神经科学.
- 临床医学 临床医学
- 疼痛研究 疼痛研究
背景情况:
- 纤维肌痛综合征 (FMS) 是一种复杂的慢性疼痛障碍,主要影响女性,往往导致诊断不足和治疗挑战.
- 跨磁刺激 (TMS) 为优化FMS治疗提供了潜在的生物标志物,但目前的证据有限.
- 了解大脑活动和临床FMS症状之间的关系对于推进治疗策略至关重要.
研究的目的:
- 调查TMS评估的皮质刺激性和抑制标记以及FMS患者的临床特征之间的关联.
- 探索这些神经生理学标志物如何与FMS患者的疼痛严重程度,疲劳和治疗史有关.
- 为了获得关于FMS潜在的神经生物学机制的新见解.
主要方法:
- 从108名FMS患者的基线数据进行横截面分析 (88.8%为女性,平均年龄为47.3岁).
- 利用TMS来测量短内皮抑制 (SICI),运动内皮促进 (ICF) 和静止运动值 (rMT).
- 与临床数据相关的TMS指标包括疼痛严重程度,FMS持续时间,疲劳水平, gabapentinoid使用和尼古丁史.
主要成果:
- 降低SICI与 gabapentinoid使用相关,尼古丁史和疲劳增加,这表明在非疼痛FMS症状中发挥了作用.
- 增加的ICF与更高的疼痛严重程度和更短的FMS持续时间有关,这表明感觉运动通路的重组.
- 较高的rMT与减少疼痛调制 (较低的CPM) 相关,这表明疼痛抑制机制受损.
结论:
- FMS似乎会损害大脑的抑制功能,特别是影响SICI,这与疲劳有关.
- 变化的感觉运动通路刺激性 (ICF) 可能反映出FMS中慢性疼痛的适应性.
- 疼痛补偿机制 (rMT,CPM) 的破坏是显而易见的,可能会被 gabapentinoids 和尼古丁加剧.
相关概念视频
Sedatives and Hypnotics Drugs: Miscellaneous Agents
151
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
151
Analgesia and Pain Management
547
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
547
Spasmolytic Agents: Chemical Classification
869
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
869
Drug Abuse and Addiction: Pharmacological Phenomena
447
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
447
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
Desensitization and Tachyphylaxis
1.6K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.6K


